Effects of prostaglandin E1 infusion in the pre-operative management of critical congenital heart disease.
Prostaglandin E1 (PGE1) was administered to 27 infants in whom pulmonary or systemic blood flow was entirely or significantly dependent upon the patency of the ductus arteriosus. In 12 patients with pulmonary atresia or severe pulmonary stenosis, PGE1 infusion was followed by an improvement in hypoxemia and acidemia (group I). In 2 patients with left ventricular outflow-tract obstruction, PGE1 infusion was followed by an improvement in arterial blood pressure, peripheral perfusion and urine output (group II). In 5 patients with d-transposition of the great arteries and intact ventricular septum who had persistent severe hypoxemia after creation of an interatrial communication, PGE1 infusion improved the arterial oxygenation with dilatation of the ductus arteriosus (group III). Seven patients (3 of group I, 2 of group II and 2 of group III) failed to respond to PGE1. There were no fatal side effects. It is concluded that PGE1 therapy is highly effective in stabilizing pre-operative conditions of infants with ductus-dependent congenital heart disease.
D000527:Alprostadil; D004374:Ductus Arteriosus, Patent / Q000188:drug therapy / Q000601:surgery; D006330:Heart Defects, Congenital / Q000188:drug therapy / Q000601:surgery*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D011300:Preoperative Care; D011458:Prostaglandins E / Q000008:administration & dosage / Q000627:therapeutic use*
D011458:Prostaglandins E; D000527:Alprostadil